- AstraZeneca India Net Loss: The company reported a net loss of 117.9 million rupees for the first quarter.
- Previous Year Comparison: This is a significant drop from a profit of 538.6 million rupees in the same quarter the previous year.
- Revenue Growth: Despite the loss, revenue increased by 32% year-over-year, reaching 3.88 billion rupees.
- Rising Costs: Total costs for the quarter surged by 52% year-over-year, amounting to 3.53 billion rupees.
- Exceptional Loss: The first quarter results include a one-time exceptional loss of 575.6 million rupees due to the provision for the closure of a manufacturing site that couldn’t be sold.
- Share Performance: Shares of AstraZeneca India fell by 4.2%, closing at 6,790 rupees with 40,694 shares traded.
- Market Sentiment: There were no new buy, hold, or sell recommendations issued for the stock.
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts assessing AstraZeneca PLC‘s long-term outlook have highlighted its strong momentum, scoring a solid 5 in this factor. This indicates positive market momentum and performance trends, suggesting a promising future for the company. Combined with a growth score of 4, AstraZeneca is positioned to capitalize on opportunities for expansion and development within the pharmaceutical industry.
Despite moderate scores in areas such as value and dividend, AstraZeneca’s focus on therapeutic areas like oncology and cardiovascular health provides a sturdy foundation for resilience, as indicated by a score of 2 in this category. This diverse portfolio of products positions AstraZeneca well for potential challenges in the market. Overall, the company’s strategic positioning and strong growth and momentum scores signal a favorable outlook for AstraZeneca PLC in the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
